Novel biomimetic mesoporous silica nanoparticles system possessed targetability and immune synergy to promote solid tumor immuno- chemotherapy efficacy

New strategies enhancing both targetability of chemotherapy drugs and synergistic effects of chemotherapy and immunotherapy remain a major challenge for the solid tumor therapy. In this research, a novel biomimetic nanoparticle system possessed function of tumor targeting and immune synergy was designed to accomplish the above requirements. The membranes was coated on mesoporous silica nanoparticles loaded with chemotherapy drugs named doxorubicin (DOX); and it was modified by the glycosyl-phosphatidylinositol (GPI) anchored anti-HER2 single chain variable fragment (scFv) and the GPI anchored co-stimulatory molecule CD80 to promote solid tumor targeted chemotherapy and cooperated immunotherapy, respectively. The effects of as-prepared nano therapeutic system in both tumor targeted chemotherapy and collaborated cellular immune response were investigated through in vitro and in vivo experiments. The results showed that the novel biomimetic therapeutic system can significantly promote antitumor efficiency in vitro and in vivo experiments. Besides, this therapeutic system further enhances antitumor capacity by increasing the CD8+ T-cell activation and the cytokine production and reducing the myeloid-derived suppressor cells (MDSCs) levels in tumors.